These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29267138)

  • 1. Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs.
    Chung JK; Spencer E; Hunt M; McCauley T; Welty D
    J Ocul Pharmacol Ther; 2018; 34(1-2):224-232. PubMed ID: 29267138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifitegrast for the treatment of dry eye disease in adults.
    Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
    Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs.
    Acheampong AA; Shackleton M; Tang-Liu DD; Ding S; Stern ME; Decker R
    Curr Eye Res; 1999 Feb; 18(2):91-103. PubMed ID: 10223652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program.
    Chan CC; Prokopich CL
    J Pharm Pharm Sci; 2019; 22(1):49-56. PubMed ID: 30636670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits.
    Tajika T; Isowaki A; Sakaki H
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):43-9. PubMed ID: 21118027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
    Tong AY; Passi SF; Gupta PK
    Eye Contact Lens; 2020 Jan; 46 Suppl 1():S20-S24. PubMed ID: 30985492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of an LC-MS/MS method for quantification of lifitegrast in rabbit plasma and ocular tissues and its application to pharmacokinetic study.
    Kim E; Jang E; Jung W; Kim W; Lee J; Choi DH; Shin BS; Shin S; Kim TH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123892. PubMed ID: 37788538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent.
    Roy Chowdhury U; Pervan-Steel CL; Sheeler R; Sookdeo HK; Rogers B; Casale R; Dosa PI; Htoo T; Wirostko BM; Fautsch MP
    J Ocul Pharmacol Ther; 2023 Jun; 39(5):332-346. PubMed ID: 37200453
    [No Abstract]   [Full Text] [Related]  

  • 11. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits.
    Weiss SL; Kramer WG
    J Ocul Pharmacol Ther; 2019 Sep; 35(7):395-402. PubMed ID: 31355703
    [No Abstract]   [Full Text] [Related]  

  • 14. Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.
    Guimaraes de Souza R; Yu Z; Stern ME; Pflugfelder SC; de Paiva CS
    J Ocul Pharmacol Ther; 2018 Sep; 34(7):543-549. PubMed ID: 29958030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits.
    Iyer GR; Cason MM; Womble SW; Li G; Chastain JE
    J Ocul Pharmacol Ther; 2015 May; 31(4):204-10. PubMed ID: 25775192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
    Nichols KK; Donnenfeld ED; Karpecki PM; Hovanesian JA; Raychaudhuri A; Shojaei A; Zhang S
    Eur J Ophthalmol; 2019 Jul; 29(4):394-401. PubMed ID: 30112930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Sirolimus Eye Drops Following Topical Ocular Administration in Rabbits.
    Lin J; Lu Z; Wang Y; Zhang J; Guo J; Huang Y; Lin B; Yang W
    J Ocul Pharmacol Ther; 2023 Dec; 39(10):735-743. PubMed ID: 37579189
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative Assessment of Distribution Characteristics and Ocular Pharmacokinetics of Norvancomycin Between Continuous Topical Ocular Instillation and Hourly Administration of Eye Drop.
    Lin W; Zhao L; Huang X; Tan Q; Peng M; Khan MA; Lin D
    Drug Des Devel Ther; 2020; 14():867-879. PubMed ID: 32161446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular Drug Distribution and Safety of a Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in Rabbit.
    Papangkorn K; Higuchi JW; Brar B; Higuchi WI
    J Ocul Pharmacol Ther; 2018 May; 34(4):325-334. PubMed ID: 29432054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.